Which is better, SANOFICONR.BO or TMDX?

On the Buffett-Fit framework, Sanofi Consumer Healthcare India Limited (SANOFICONR.BO) currently grades higher than TMDX — 78/100 (B grade) vs 51/100 (D). That said, "better" depends on which framework you trust — SANOFICONR.BO wins on Warren Buffett, Benjamin Graham, Philip Fisher, Joel Greenblatt, Charlie Munger, and Terry Smith; TMDX wins on Peter Lynch. The full pillar breakdown is on this page.

Should I buy SANOFICONR.BO or TMDX?

This page is an educational comparison, not investment advice. Both SANOFICONR.BO and TMDX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is SANOFICONR.BO better than TMDX for value investing?

On the Buffett-style value-investing framework, SANOFICONR.BO currently grades higher — 78/100 vs 51/100, a 27-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between SANOFICONR.BO and TMDX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). SANOFICONR.BO currently scores 78/100 (B grade); TMDX scores 51/100 (D grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, SANOFICONR.BO or TMDX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. SANOFICONR.BO and TMDX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, SANOFICONR.BO or TMDX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are SANOFICONR.BO and TMDX both Healthcare stocks?

Yes — both Sanofi Consumer Healthcare India Limited (SANOFICONR.BO) and TransMedics Group, Inc. (TMDX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this SANOFICONR.BO vs TMDX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Sanofi Consumer Healthcare India Limited

SANOFICONR.BO$104.98BHealthcare Market cap, Sector

TransMedics Group

TMDX$2.77BHealthcare Market cap, Sector

Overall winner

Sanofi Consumer Healthcare India Limited

SANOFICONR.BO 61 TMDX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

SANOFICONR.BO6wins

1winsTMDX

Warren Buffett

78B

D51

Benjamin Graham

89A

D57

Philip Fisher

83B

D52

Peter Lynch

77B

B80

Joel Greenblatt

91A

F44

Charlie Munger

86A

D50

Terry Smith

85A

F43

Side-by-side metrics

Metric	SANOFICONR.BO	TMDX
Market cap	Winner: $104.98B	$2.77B
P/E (TTM)	44.0x	12.6x Winner
EV/EBIT	31.7x	23.4x Winner
ROIC (TTM)	Winner: 59.15%	6.94%
Gross margin	Winner: 68.13%	59.09%
Net margin	Winner: 27.35%	27.04%
Revenue CAGR 5y	27.01%	111.5% Winner
EPS CAGR 5y	20.67%	-
Debt / Equity	Winner: 0.1x	1.7x
Dividend yield	-	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

SANOFICONR.BO leads on

Market cap$104.98Bvs $2.77B+97%
Debt / Equity0.1xvs 1.7x+96%
ROIC (TTM)59.15%vs 6.94%+88%
Gross margin68.13%vs 59.09%+13%

TMDX leads on

Revenue CAGR 5y111.5%vs 27.01%+76%
P/E (TTM)12.6xvs 44.0x+71%
EV/EBIT23.4xvs 31.7x+26%

More like SANOFICONR.BO

SANOFICONR.BO vs 1681.HK SANOFICONR.BO vs SANOFICONR.NS SANOFICONR.BO vs PME.AX SANOFICONR.BO vs CAMX.ST

More like TMDX

TMDX vs 1681.HK TMDX vs SANOFICONR.NS TMDX vs PME.AX TMDX vs CAMX.ST

Read the full Buffett-Brain analysis for SANOFICONR.BO Read the full Buffett-Brain analysis for TMDX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Side-by-side metrics

Metric	SANOFICONR.BO	TMDX
Market cap	Winner: $104.98B	$2.77B
P/E (TTM)	44.0x	12.6x Winner
EV/EBIT	31.7x	23.4x Winner
ROIC (TTM)	Winner: 59.15%	6.94%
Gross margin	Winner: 68.13%	59.09%
Net margin	Winner: 27.35%	27.04%
Revenue CAGR 5y	27.01%	111.5% Winner
EPS CAGR 5y	20.67%	-
Debt / Equity	Winner: 0.1x	1.7x
Dividend yield	-	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

SANOFICONR.BO leads on

Market cap$104.98Bvs $2.77B+97%
Debt / Equity0.1xvs 1.7x+96%
ROIC (TTM)59.15%vs 6.94%+88%
Gross margin68.13%vs 59.09%+13%

TMDX leads on

Revenue CAGR 5y111.5%vs 27.01%+76%
P/E (TTM)12.6xvs 44.0x+71%
EV/EBIT23.4xvs 31.7x+26%